US-based clinical trials laboratory services organisation Q2 Solutions’ EA Genomics has entered into an agreement with Illumina to create a framework to develop next-generation sequencing-based (NGS) CDx assays.
The expansion of Q2 Solutions’ CDx development portfolio will boost its wide range of end-to-end services that extend from biomarker discovery and development to the application of precision medicine through its clinical trials laboratory network.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the agreement, Q2 Solutions will develop NGS assays using Illumina’s MiSeqDx instrument.
Approved by the US Food and Drug Administration (FDA), the MiSeqDx is an NGS instrument used for in vitro diagnostic purposes in clinical laboratories.
This partnership will combine Q2 Solutions’ global experience and local knowledge, as well as its genomic, scientific and medical expertise, with Illumina’s ability to apply innovative technologies to the analysis of genetic variation and function.
Q2 Solutions CEO Costa Panagos said: “At Q2 Solutions, we partner with our customers to bring innovative solutions to meet the needs of patients across the world.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted and accurate therapies are critical.
“Q2 Solutions helped develop 62% of all FDA-approved precision medicine drugs of 2015, and we look forward to the opportunity to continue working with our customers on an approach that can help improve healthcare globally.”
